Pfizer, Merck KGaA's Bavencio takes a hit with second ovarian cancer failure

Pfizer and Merck KGaA's Bavencio failed a separate phase 3 ovarian cancer trial in November. (Pfizer)

Back in November, Pfizer and Merck KGaA reported that immuno-oncology drug Bavencio had failed a late-stage ovarian cancer trial. And now the companies can make it two.

Friday, the partners said they’d scrapped a phase 3 study examining Bavencio in combination with and/or after chemo in previously untreated patients after the drug showed it couldn’t stave off cancer progression.

RELATED: Pfizer, Merck KGaA's Bavencio flunks another trial, this time in ovarian cancer

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The flop follows close on the heels of another trial misfire in ovarian cancer. Last month, the Pfizer-Merck KGaA team said Bavencio had failed to keep cancer at bay or prolong life on its own or in tandem with chemo in previously treated patients.

The setbacks haven’t been what Bavencio’s makers want to see. The company is lagging well behind PD-1/PD-L1 rivals from Merck, Bristol-Myers Squibb, Roche and AstraZeneca, which have each made inroads in blockbuster markets. Bavencio, meanwhile, bears just two FDA approvals—one in an immensely crowded bladder cancer market and the other in Merkel cell carcinoma, a rare type of skin cancer that Merck superstar Keytruda just picked up an OK to treat.

One reason? Outside of ovarian cancer, it’s failed a trio of other trials: one testing it in a range of solid tumors alongside an immuno-oncology candidate dubbed 4-1BB, one in third-line gastric cancer and one in second-line lung cancer.

RELATED: Pfizer preps for Bristol-Myers Squibb showdown with Bavencio kidney cancer combination data

The drug has posted one recent positive performance in the clinic, coming up with data showing that, when paired with Pfizer’s Inlyta, it could ward off kidney cancer progression in previously untreated patients by a median 13.8 months, compared to 8.4 months for Pfizer standard-of-care drug Sutent. But Keytruda is threatening to break into that arena, too.

For now, Pfizer and Merck KGaA aren’t giving up on Bavencio’s ovarian cancer prospects altogether. They’re still testing the drug in combination with Pfizer’s Talzenna, a member of the PARP inhibitor class that’s made waves in ovarian cancer treatment over the last few years. Talzenna, though, is the only approved member of the class without an ovarian cancer indication to its name. And meanwhile, Merck is taking a similar approach, trialing Keytruda along PARP leader Lynparza, a drug it shares with AstraZeneca.

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.